Lionshead Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.16M Buy
969
+23
+2% +$23.5K 0.75% 39
2026
Q1
$870K Sell
946
-8
-0.8% -$8.11K 0.64% 40
2025
Q4
$1.03M Buy
954
+20
+2% +$19.1K 0.77% 39
2025
Q3
$713K Buy
934
+366
+64% +$272K 0.57% 48
2025
Q2
$443K Buy
568
+25
+5% +$19.4K 0.41% 62
2025
Q1
$448K Sell
543
-44
-7% -$36.6K 0.47% 55
2024
Q4
$453K Buy
+587
New +$486K 0.33% 60

Other funds holding LLY

Lionshead Wealth Management's LLY Position: Q2 2026 in Review

Lionshead Wealth Management increased its Eli Lilly (LLY) stake by 2.4% in Q2 2026, buying an estimated $23.5K and bringing the position to 969 shares worth $1.16M. The position accounts for 0.75% of the portfolio, ranked #39.

Lionshead Wealth Management first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Lionshead Wealth Management held 969 shares of Eli Lilly worth $1.16M as of Q2 2026.
  • Lionshead Wealth Management bought 23 Eli Lilly shares in Q2 2026, an estimated $23.5K.
  • Eli Lilly made up 0.75% of Lionshead Wealth Management's portfolio in Q2 2026, its #39 holding.
  • Lionshead Wealth Management first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Lionshead Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.